Code: 06441191

Tuberculosis & Multidrug-Resistant Tuberculosis

Name: Tuberculosis & Multidrug-Resistant Tuberculosis
Brand: Nova Science Publishers Inc
SKU: 06441191
Price: 155.57 EUR
Availability: BackOrder
Author: Eiman Mokaddas
ISBN: 9781628083095

by Eiman Mokaddas, Suhail Ahmad

Language: English
Binding: Hardback
Number of pages: 121
Publisher: Nova Science Publishers Inc, 2013
More about this

155.57 €

RRP: 172.82 €

You save 17.25 €

Availability:

50/50

We think title might be available. Upon your order we will do our best to get it within 6 weeks.
We search the world

Availability alert

Add to wishlist

To Live
17.28 € -20 %
Buy
Regenerative Design for Sustainable Development
84.91 € -2 %
Buy
Shaky Colonialism
36.18 €
Buy
Technological Change and the Future of Warfare
27.18 €
Buy
Design in the Borderlands
88.65 €
Buy
What Every Teacher Should Know About Special Learners
21.83 € -10 %
Buy
Project X Origins: Grey Book Band, Oxford Level 12: Dilemmas and Decisions: Class Pack of 30
311.06 €
Buy

Give this book as a present today

Order book and choose Gift Order.
We will send you book gift voucher at once. You can give it out to anyone.
Book will be send to donee, nothing more to care about.

Book gift voucher sample Read more

Availability alert

We will watch availability for you

Enter your e-mail address and once book will be available,
we will send you a message. It's that simple.

More about Tuberculosis & Multidrug-Resistant Tuberculosis

Book details
Synopsis
Trending among others

You get 377 loyalty points

Book synopsis

Tuberculosis (TB), causing nine million active disease cases and 1.5 million deaths every year, is a formidable public health challenge, particularly in poor and developing countries around the world. Major reasons for global burden of TB include association of active disease with human immunodeficiency virus (HIV) coinfection or other underlying immunosuppressive conditions such as diabetes and increasing incidence of drug-resistant, multidrug-resistant (MDR) (resistant at least to rifampicin and isoniazid) and extensively drug-resistant (XDR) (additionally resistant to a fluoroquinolone plus kanamycin/amikacin/capreomycin) strains of M. tuberculosis. While treatment of drug-susceptible TB is effective in >95 percent of disease cases, supervised therapy for >6 months is challenging. Inadequate/inappropriate therapy due to inability of poor patients to pay for drugs and non-adherence to treatment (regimen and duration) often results in much lower cure rates and evolution of drug-resistant strains of M. tuberculosis due to mutations occurring at a predictable rate in genes encoding drug targets. Sequential accumulation of mutations results in evolution of MDR and XDR strains of M. tuberculosis. Today, drug-resistant TB and MDR-TB have become prevalent in many parts of the world and XDR-TB strains are emerging rapidly. While MDR-TB is difficult to treat, XDR-TB is untreatable in most developing countries.